Ironwood Pharmaceuticals Inc. (IRWD)

8.88
0.14 1.60
NASDAQ : Health Technology
Prev Close 8.74
Open 8.85
Day Low/High 8.72 / 8.93
52 Wk Low/High 7.91 / 15.31
Volume 755.04K
Avg Volume 1.96M
Exchange NASDAQ
Shares Outstanding 156.50M
Market Cap 1.42B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ironwood Pharmaceuticals To Present At Upcoming September Investor Conferences

Ironwood Pharmaceuticals To Present At Upcoming September Investor Conferences

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in September: 2019 Wells Fargo Healthcare Conference on Wednesday, September 4, 2019 at 2:25 p.

Ironwood Pharmaceuticals Announces Full Exercise Of Convertible Notes Over-Allotment

Ironwood Pharmaceuticals Announces Full Exercise Of Convertible Notes Over-Allotment

Ironwood Pharmaceuticals, Inc. ("Ironwood") (Nasdaq: IRWD), a GI-focused healthcare company, today announced that, in connection with its previously announced offering of 0.

Ironwood Pharmaceuticals And Alnylam Pharmaceuticals Enter U.S. GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP)

Ironwood Pharmaceuticals And Alnylam Pharmaceuticals Enter U.S. GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc.

Alnylam Pharmaceuticals And Ironwood Pharmaceuticals Enter U.S. GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP)

Alnylam Pharmaceuticals And Ironwood Pharmaceuticals Enter U.S. GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals Announces Pricing Of Upsized $350 Million Convertible Senior Notes Offering

Ironwood Pharmaceuticals Announces Pricing Of Upsized $350 Million Convertible Senior Notes Offering

Ironwood Pharmaceuticals, Inc. ("Ironwood") (Nasdaq: IRWD), a GI-focused healthcare company, today announced the pricing of $175 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2024 (the "2024 Notes")...

Ironwood Pharmaceuticals Announced Proposed Offering Of $330 Million Of Convertible Senior Notes

Ironwood Pharmaceuticals Announced Proposed Offering Of $330 Million Of Convertible Senior Notes

Ironwood Pharmaceuticals, Inc. ("Ironwood") (Nasdaq: IRWD), a GI-focused healthcare company, today announced that it intends to offer, subject to market and other conditions, $165 million aggregate principal amount of convertible senior unsecured notes...

Ironwood Pharmaceuticals Reports Second Quarter 2019 Results

Ironwood Pharmaceuticals Reports Second Quarter 2019 Results

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its second quarter 2019 results and recent business activities.

Ironwood Pharmaceuticals To Host Second Quarter 2019 Investor Update Call

Ironwood Pharmaceuticals To Host Second Quarter 2019 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2019 investor update conference call and webcast at 4:30 p.

Ironwood And Allergan Report Positive Topline Data From Phase IIIb Trial Of LINZESS® (linaclotide) In Adults With Irritable Bowel Syndrome With Constipation (IBS-C)

Ironwood And Allergan Report Positive Topline Data From Phase IIIb Trial Of LINZESS® (linaclotide) In Adults With Irritable Bowel Syndrome With Constipation (IBS-C)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and  Allergan plc (NYSE:AGN) today announced positive topline data from a Phase IIIb clinical trial evaluating LINZESS (linaclotide) 290 mcg on multiple abdominal symptoms in adult patients with IBS-C.

Ironwood Pharmaceuticals To Establish New Headquarters In Downtown Boston

Ironwood Pharmaceuticals To Establish New Headquarters In Downtown Boston

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the company plans to relocate its headquarters to a new office in downtown Boston from its current location in Cambridge, Massachusetts.

Ironwood Pharmaceuticals And Allergan Initiate Patient Dosing In Phase II Clinical Trial Of MD-7246 In Patients With Abdominal Pain Associated With IBS-D

Ironwood Pharmaceuticals And Allergan Initiate Patient Dosing In Phase II Clinical Trial Of MD-7246 In Patients With Abdominal Pain Associated With IBS-D

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the initiation of patient dosing in a Phase II clinical trial evaluating MD-7246 in patients with abdominal pain associated with irritable bowel syndrome with...

Ironwood Pharmaceuticals To Highlight IW-3718 And Linaclotide Data At Digestive Disease Week® 2019

Ironwood Pharmaceuticals To Highlight IW-3718 And Linaclotide Data At Digestive Disease Week® 2019

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present clinical data for IW-3718, and both clinical and non-clinical data for linaclotide during Digestive Disease...

Ironwood Pharmaceuticals To Present At The 2019 Bank Of America Merrill Lynch Healthcare Conference

Ironwood Pharmaceuticals To Present At The 2019 Bank Of America Merrill Lynch Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2019 Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 14, 2019 at 8:00 a.

Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA From Continuing Operations Guidance

Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA From Continuing Operations Guidance

Ironwood Pharmaceuticals, Inc. (Nasdaq:IRWD), a GI-focused healthcare company, today provided an update on its first quarter 2019 results and recent business activities.

Ironwood Pharmaceuticals To Host First Quarter 2019 Investor Update Call

Ironwood Pharmaceuticals To Host First Quarter 2019 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2019 investor update conference call and webcast at 8:30 a.

Ironwood Pharmaceuticals Completes Separation Of Cyclerion Therapeutics And Becomes A Gastrointestinal (GI)-focused Healthcare Company

Ironwood Pharmaceuticals Completes Separation Of Cyclerion Therapeutics And Becomes A Gastrointestinal (GI)-focused Healthcare Company

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that it has completed the tax-free spin-off of its soluble guanylate cyclase (sGC) business, Cyclerion Therapeutics, Inc.

Interesting IRWD Put And Call Options For November 15th

Interesting IRWD Put And Call Options For November 15th

Investors in Ironwood Pharmaceuticals Inc saw new options begin trading this week, for the November 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ironwood Announces Effectiveness Of Cyclerion Form 10 Registration Statement

Ironwood Announces Effectiveness Of Cyclerion Form 10 Registration Statement

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that the Form 10 Registration Statement filed by Cyclerion Therapeutics, Inc.

Ironwood Pharmaceuticals To Present At Barclays Global Healthcare Conference

Ironwood Pharmaceuticals To Present At Barclays Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Barclays Global Healthcare Conference on Thursday, March 14, 2019 at 2:35 p.

Ironwood Pharmaceuticals To Present At Cowen Health Care Conference

Ironwood Pharmaceuticals To Present At Cowen Health Care Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 39 th Annual Cowen Health Care Conference on Monday, March 11, 2019 at 4:10 p.

Cyclerion, The Planned R&D Spin-off Of Ironwood Pharmaceuticals, Secures Commitments Of $175 Million In Private Offering

Cyclerion, The Planned R&D Spin-off Of Ironwood Pharmaceuticals, Secures Commitments Of $175 Million In Private Offering

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Cyclerion Therapeutics, Inc.

Ironwood Pharmaceuticals To Present At SVB Leerink Global Healthcare Conference

Ironwood Pharmaceuticals To Present At SVB Leerink Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.

Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2018 Investor Update

Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2018 Investor Update

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a commercial biotechnology company, today provided an update on its fourth quarter and full year 2018 results and recent business activities.

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2018 Investor Update Call

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2018 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2018 investor update conference call and webcast at 8:30 a.

Ironwood Announces Filing Of Form 10 Registration Statement In Connection With Planned Business Separation

Ironwood Announces Filing Of Form 10 Registration Statement In Connection With Planned Business Separation

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the filing by Cyclerion Therapeutics, Inc.

Ironwood Pharmaceuticals Announces Board Of Directors For Ironwood And Cyclerion, Effective Following Separation

Ironwood Pharmaceuticals Announces Board Of Directors For Ironwood And Cyclerion, Effective Following Separation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the composition of the Ironwood and Cyclerion Therapeutics, Inc.

Ironwood Pharmaceuticals Initiates Phase 1 Trial Of IW-6463, The First CNS-penetrant SGC Stimulator To Enter Clinical Trials

Ironwood Pharmaceuticals Initiates Phase 1 Trial Of IW-6463, The First CNS-penetrant SGC Stimulator To Enter Clinical Trials

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers.

Ironwood Pharmaceuticals Announces Approval Of LINZESS® (linaclotide) In China For The Treatment Of Adults With IBS-C

Ironwood Pharmaceuticals Announces Approval Of LINZESS® (linaclotide) In China For The Treatment Of Adults With IBS-C

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a commercial biotechnology company, today announced that the National Medical Products Administration (NMPA) approved the marketing application for LINZESS® (linaclotide) for adults with irritable bowel...

TheStreet Quant Rating: D- (Sell)